SUPPLY of LUTATHERA® (lutetium Lu 177 dotatate) and PLUVICTO™ (lutetium Lu 177 vipivotide tetraxetan)
DEFENSE HEALTH AGENCY
Clinical Utility: It is used for targeted radioligand therapy for specific types of prostate cancer within the Nuclear Medicine Division of the Department of Radiology at WRNMMC. Novartis Pharmaceuticals Corporation is the sole source for Pluvicto. Therefore, the recommended course of action is to award a contract directly to Novartis. This approach is deemed to be in the government's best interest to ensure the seamless delivery of these critical supplies and maintain continuity of patient care at WRNMMC. The acquisition will be treated as a sole-source procurement.
AI proposal generator
Generate a structured solution proposal in 90 seconds
Kimi drafts an 8-section bid response — exec summary, technical approach, compliance matrix, indicative pricing, timeline, why-we-win — tailored to your company profile and this exact tender.
Related opportunities
Similar tenders
Pointwise Software Renewal
FA2823 AFTC PZIO
48--ACTUATOR,ELECTRO-ME - AND OTHER REPLACEMENT PARTS
SPRMM1 DLA MECHANICSBURG
Design-Build Services for the Bridge of the Americas (BOTA) Land Port of Entry (LPOE) Modernization Project, El Paso, Texas
48--VALVE ASSEMBLY,MANI, IN REPAIR/MODIFICATION OF
NAVSUP WEAPON SYSTEMS SUPPORT MECH
Plastic Insignia Buttons
COMMANDER
Free tender alerts
Get a weekly digest of United States tenders
New United States tenders matching your interests, delivered to your inbox once a week — no app required. Add keywords and we'll filter the digest to match.